Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chromosome 1 abnormalities in multiple myeloma.

Youna Marzin1, Déborah Jamet, Nathalie Douet-Guilbert

  • 1Laboratoire d'Histologie, Embryologie et Cytogénétique, Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France.

Anticancer Research
|April 20, 2006
PubMed
Summary

Chromosome 1 abnormalities are common in multiple myeloma (MM), a B-cell cancer. Deletions on the short arm (1p) and gains on the long arm (1q) are frequently observed, impacting MM pathogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<sup>18</sup>F-FDG PET radiomic analysis to predict outcomes in metastatic melanoma treated with immune checkpoint inhibitors.

Frontiers in immunology·2026
Same author

Chromoanasynthesis.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Sperm DNA Fragmentation as a Marker of Chromoanagenesis Occurrence During Spermatogenesis.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.

Melanoma research·2025
Same author

Zn<sup>2+</sup> triazamacrocyclic chelators with methylpyridine pendant arms for B-cell apoptosis: a structure-activity study.

Dalton transactions (Cambridge, England : 2003)·2025
Same author

Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.

Frontiers in nuclear medicine·2024

Area of Science:

  • Hematology
  • Cancer Genetics
  • Cytogenetics

Background:

  • Multiple myeloma (MM) is a B-cell malignancy comprising 10% of hematological cancers.
  • Chromosome 1 aberrations are frequently observed in MM pathogenesis.

Purpose of the Study:

  • To investigate the role of chromosome 1 abnormalities in multiple myeloma.
  • To characterize the types and locations of chromosome 1 aberrations in MM patients.

Main Methods:

  • Conventional cytogenetics and fluorescence in situ hybridization (FISH) were used.
  • Abnormalities were categorized into balanced translocations, deletions, amplifications, and jumping translocations (JT).

Main Results:

  • Deletions at 1p11-1p21 (27%) and gains at 1q31-1qter (54%) were the most common.

Related Experiment Videos

  • Jumping translocations (JT) frequently involved the entire long arm of chromosome 1.
  • Specific regions on 1p and 1q showed preferential involvement, suggesting roles for tumor suppressor genes and oncogenes.

    • Conclusions:

    • Chromosome 1 abnormalities are significant contributors to multiple myeloma development.
    • 1p deletions may lead to hemizygosity of tumor suppressor genes.
    • 1q gains could result in oncogene overexpression, driving MM progression.